Share on

Global Antibiotics Market Size, Share, Trends, COVID-19 Impact and Growth Analysis Report – Segmented By Action Mechanism, Drug Class and Region (North America, Europe, Asia pacific, Latin America, Middle East and Africa) – Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 10117
Pages: 160
Formats: report pdf report excel report power bi report ppt

Antibiotics Market Size (2022 to 2027)

As per our research analysis report, the global antibiotics market is expected to reach USD 57.4 billion by 2027, growing at a 4.0% CAGR from 2022 to 2027.

Antibiotics are antimicrobials that fight bacterial illnesses and, on rare occasions, protozoan infections. Because antibiotics are the most prevalent antibacterial agent, they are widely used to treat and prevent bacterial infections. These compounds have the potential to kill or inhibit bacteria. They're also used to treat strep throat, urinary tract infections, sinus infections, pneumonia, skin infections, and other illnesses. Antibiotics are classified in various ways, the most popular of which is based on their chemical structures, range of activity, and mode of action.


Y-O-Y growth in the incidence of infectious diseases and increasing government support drive the global antibiotics market growth.

Y-O-Y growth in the incidence of chronic disorders, rising demand for new antibiotics, and risk investments for research in developing drugs for multi-resistant pathogens are a few other significant factors boosting the global antibiotics market. Also, government officials' support is expected to improve the development of generic antibiotics, ultimately fueling the growth rate of the global antibiotics market.

The increased efforts of pharmaceutical companies for new therapies to treat infectious diseases is a big plus to the global antibiotics market growth.

Introducing new antibiotic drugs and collaborating key market players with other companies to develop better antibiotic products are expected to fuel the market's growth rate. Furthermore, pharmaceutical companies' cooperation in developing new therapies to limit the pricing pressure and increased initiatives of various governments to develop new therapies in treating drug-resistant propel the market growth.  For instance, in March 2019, the Global Antibiotic Research and Development Partnership (GARDP) disclosed the private partnership with Evotec AG to develop first-in-class antibiotics for treating drug-resistant bacterial infections.

Increased investment from producers to produce new medicines drives the worldwide demand for the antibiotics market.

However, the unruly and sustained application of antibiotics in the last few decades has contributed to the growth of antibiotic-resistant bacteria and pathogens. Infections such as measles, pneumonia, and gonorrhea, which were originally susceptible to antibiotics, were resistant. However, the global antibiotics market is projected to grow substantially due to the discovery of innovative molecules and new hybrid therapies to treat antibiotic-resistant microbial infections. Advances in antibiotic drugs and new hybrid treatments for antibiotic-resistant microbial infections are driving the development. For this, a special classification by the regulatory authority of multiple prospective pharmaceutical firms is one of the factors projected to fuel the global antibiotics market growth.

Collaborations on the development of antibiotics are projected to contribute to developing a high number of antibiotic drugs.

The acquisition and cooperation of various producers drive the global demand for antibiotic drugs. In addition, the growing number of public-private partnerships in which public bodies offer financing and creative R&D approaches to antibiotic-developing companies is expected to improve the product pipeline. Growing the prevalence of chronic and infectious diseases worldwide and improving the effectiveness of antibiotics that can cure a wide range of bacterial infections such as pneumonia, malaria, and tuberculosis, and the gap in the demand and supply of antibiotics are the other factors that have contributed to the exponential growth of the global antibiotics market.


Strict regulatory rules for the acceptance of new products are inhibiting the growth of the antibiotics market.

In addition, the side effects triggered by antibiotic drugs and the lack of knowledge among people about antibiotic drugs impede the growth of the antibiotics market. Nonetheless, continuing clinical trials are being performed by various pharmaceutical firms and would increase the demand for antibiotics in the future.

COVID-19 Impact on the global antibiotics market:

COVID-19 affects individuals of all ages, most of whom experience mild to severe symptoms. The epidemic is increasing worldwide, and the rate of deaths is high. Unfortunately, antimicrobial care for patients with SARS-CoV-2 infection is rare. While antimicrobials have been documented in research, there is inadequate consideration of their value or the risk that they may be used indiscriminately or incorrectly, mainly when combined with broad-spectrum antibiotics. Still, the spread of COVID-19 across the globe was followed by improved antibiotic use.

The results are focused on estimates that up to 95% of COVID-19 patients are prescribed antibiotics as part of their care and fear that such large-scale opioid use may have more considerable environmental consequences. However, following the start of the COVID-19 pandemic, there has been increasing worry about the possible rise in AMR secondary to expanded antibiotic prescribing in COVID-19 patients. Other antibiotics also suggested for the treatment of COVID-19 include azithromycin, quercetin, rapamycin, and doxycycline. However, hydroxychloroquine (a chloroquine derivative considered an ancient antimalarial drug) and azithromycin proved to be much more successful in treating COVID-19. Azithromycin also prevents the replication of other viruses such as Zika and Zika. Azithromycin, doxycycline, and rapamycin are antibiotic medications that block protein synthesis and reduce inflammation and viral replication.




Market Size Available

2020 to 2026

Base Year


Forecast Period

2021 to 2026

Segments Covered

Based on action metabolism, drug call, and region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global antibiotics market has been segmented and sub-segmented into the following categories:

Antibiotics Market – By Action Mechanism:

  • Cell Wall Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Rna Synthesis Inhibitors
  • Mycolic Acid Synthesis Inhibitors
  • Folic Acid Synthesis Inhibitors

Cell wall synthesis inhibitors are expected to maintain dominance throughout the forecast period. High consumption based on prescription trends and significant government expenditures drives this market. Antibiotics that inhibit cell wall construction are the most widely used because they offer a broad spectrum of effectiveness against gram-positive and gram-negative bacteria. Due to increased research activity and government support, cell wall synthesis inhibitors are predicted to develop significantly throughout the forecast period. The drugs prevent the bacteria from synthesizing a molecule in the cell wall called peptidoglycan, which provides the cell wall with the strength to survive in the human body. Therefore, these drugs are expected to grow at the fastest rate.

Many antibiotic drugs work to inhibit DNA synthesis and the transformation of DNA into RNA. It is a significant discovery as it can help cure many natural diseases we could not fix. These types of drugs have the second-largest share.

The drugs shown to inhibit mycolic acid biosynthesis are isoniazid and triclosan. Besides, pyrazinamide was shown to inhibit fatty acid synthase type I, which, in turn, provides precursors for fatty acid elongation to long-chain mycolic acids by fatty acid synthase II. Essential for viability and virulence, enzymes in mycolic acid biosynthesis represent novel targets for drug development.

Folic acid helps the body to maintain and produce new cells. Many antibiotics are now on the market, inhibiting the folic acid synthesis and reducing excessive cell generation. Due to fewer known diseases, the drugs have the lowest market share but soon can overtake others as we identify new conditions.

Antibiotics Market – By Drug Class:

  • Cephalosporins
  • Penicillins
  • Fluoroquinolones
  • Macrolides
  • Carbapenems
  • Aminoglycosides
  • Sulfonamides
  • Others

The other antibiotics segment includes tetracyclines, imidazoles, lincosamides, and monoclonal antibodies and is projected to grow at the highest CAGR during the forecast period. The development of monoclonal antibodies for individuals with antibiotic resistance is a key highlight of this segment. Penicillin is the oldest drug to be discovered and still holds a significant share in the market. The cephalosporins have the largest market share ahead of penicillin. Increasing incidence of pneumonia, bloodstream infections, and Urinary Tract Infections (UTI) is anticipated to foster the carbapenems class of antibiotics.

Antibiotics Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

The Asia Pacific is the global antibiotics market leader as they have extensive production facilities in countries like India. The ability to produce drugs in large quantities drives the antibiotics market's growth, and the Asia Pacific will remain the leader during the forecast period. In addition, the need to cater to large populations can make the companies self-sustained, giving room for other companies in other countries. The Asia Pacific had the largest share in the global antibiotics market, predicted to rise substantially over the forecast period. This is due to increased antibiotic use, a rise in infectious diseases, and an increase in government programs to find novel treatments for drug-resistant infections. Furthermore, the presence of generic companies aids in expanding the regional market. India and China are the region's leading markets for antibiotics. Unregulated sales and excessive antibiotic consumption are the key factors driving market expansion in these countries.

On the other hand, North America is expected to develop at the fastest rate throughout the forecast period due to established market players' efforts to extend their presence in this area. These markets are heavily regulated, and the healthcare infrastructure is well-developed. The rising prevalence of infectious diseases and the government's increasing healthcare spending are two significant reasons driving the North American market. Antibiotic stewardship initiatives and boosting R&D activities of novel medicines to control infectious diseases are among the actions taken by the U.S. government.

Europe is expected to be the second-largest area in terms of market share. The rapid growth of healthcare infrastructure in various European nations increased investment in research and development activities. An increase in the number of hospitals in the region boosts demand for these pharmaceuticals in the European market. The European region is in third place, occupying a leading share in the global antibiotics market. European countries have the best medical facilities worldwide, so many are spent developing new antibiotics drugs. Europe region firms are increasing their production to cater to the world's needs. With the consistency and efficiency of drugs, the European region can be seen as a market leader in the future.


Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG are some of the promising companies in the global antibiotics market.

Antibiotics are becoming critical for human and animal life. Due to several causes, the antibiotics market has seen endless growth and opportunities. Some antibiotics are used in human and animal medicine in this pandemic and are critically important. There has been a greater than average level of antibiotic administration in a pandemic. It is vital to save the lives of COVID-19 patients, even though this requires using antimicrobials to treat or avoid complications and secondary infections.


  • In August 2016, Pfizer, Inc. agreed to purchase a part of AstraZeneca PLC's antibiotics business for USD 1.575 billion. The agreement deals with three approved antibiotics and two drugs in clinical trials—AstraZeneca handovers Pfizer all rights to sell those drugs.
  • In July 2019, a new triple-drug antibiotic called Recarbio of Merck received FDA approval for patients suffering from the complicated urinary tract and intra-abdominal infections as they have no other options.
  • In December 2020, Elecsys, an Anti-SARS-CoV-2 antibody of Roche, received the Emergency Use Authorization (EUA) from the U.S Food and Drug Administration (FDA). The test can be used to measure the level of antibodies present in people who have been exposed to the COVID 19 virus. 
  • In March 2021, the U.S. FDA approved Melinta Therapeutics Kimyrsa (Oritavancin). The antibiotic drug is for treating adults with critical acute bacterial skin and skin structure infections (ABSSSI) caused by vulnerable isolates of designated Gram-positive microorganisms. 
  • In November 2020, the National Medical Products Association (NMPA) permitted a license for drug approval for Shenzhen China Resources Gosun Pharmaceuticals Co. Ltd., license partner of Basilea Pharmaceuticals Ltd. The antibiotic drug was approved in China to treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia in adult patients.

Please wait. . . . Your request is being processed


How big is the global antibiotics market?

As per our research report, the global antibiotics market is predicted to value USD 57.4 billion by 2027.

Who is the largest manufacturer of antibiotics?

Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG are some of the largest manufacturers of antibiotics. 

Which region is expected to be the market leader in the coming years?

Across the globe, the APAC region is forecasted to be the market leader for antibiotics during the forecast period.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample